肝细胞肝癌（hepatocellular carcinoma，HCC）免疫逃逸与调节性T 细胞（Regulatory T cell, Treg）密切相关，减少Treg细胞数量及其向肿瘤组织迁移可显著抑制HCC免疫逃逸。我们前期筛选得到的治疗肝癌中药验方QHF复方，初步显示其有抑制肝癌小鼠外周Treg细胞数量和癌组织内Treg细胞特异性标志物FOXP3以及CCL20、CCR6表达的作用。鉴于此，本项目拟通过CCL20 cDNA转染技术，构建CCL20高表达肝癌细胞株和小鼠肝癌模型，采用FCM、RT-PCR、Western Blot、IHC等技术进一步验证QHF复方及各组分对癌组织中CCL20和Treg中 CCR6蛋白和基因表达等的影响，并探讨QHF复方及各组分通过CCL20/CCR6信号轴抑制Treg细胞向肿瘤迁移的分子机制和作用靶点，为寻找有效的抗肝癌免疫药物和治疗靶点提供实验依据。

The immune escape of hepatocellular carcinoma (HCC) is closely related to regulatory T cell (Treg), and the reduction of Treg cell number and its migration to tumor tissue can significantly inhibit the immune escape of HCC. QHF compound which we have screened out for the treatment of liver cancer before showed that it can inhibit the number of liver cancer Treg cells and Treg cell-specific markers FOXP3 and CCL20, CCR6 expression in cancer tissues. Therefore, CCL20 cDNA transfection technique is used to construct CCL20 high expression hepatocellular carcinoma cell lines and mouse hepatocellular carcinoma model; and FCM, RT-PCR, Western Blot, IHC and other techniques are used to further detect the effect of QHF compound and its components on the expression of CCR6 protein and gene in CCL20 and Tregs in cancer tissues, and to explore the action targets and the molecular mechanisms of QHF compound and its components inhibit the migration of Treg cells to the tumor through CCL20 / CCR6 signal axis, which will look for an effective anti-liver cancer immune drugs and therapeutic targets to provide experimental evidence.